Immune Therapeutics, Inc. Announced the Completion of the Bridging Trial

Company Also Announced the Submission of Lodonal(TM) Data for Review in Connection with the New Drug Application to NAFDAC for Use as an Immune Booster and Adjunct Treatment for Human Immunodeficiency Virus ORLANDO, FL, IMUN, / ACCESSWIRE / Immune Therapeutics Inc., a U.S. public company (OTCQB: IMUN) today announced that it has completed its 90-day bridging trail of Human Immunodeficiency Virus positive [HIV+] patients and submitted data to The National Agency for Food and Drug Administration and Control, (NAFDAC) in connection with the approval of Lodonal(TM) as an immune booster that can improve the health of those effected by human immunodeficiency virus [HIV+] and people with a comprised immune systems. The primary objectives of the clinical trial was to confirm that Lodonal(TM) is first and foremost safe for use in the local population and secondly has a beneficial effect on the immune system of patients with a compromised immune system such as HIV+ individuals. Immune enhanceme


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: